中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2011年
1期
39-41
,共3页
王伟杰%张宁妹%杜勇%李海%张东%杨银学
王偉傑%張寧妹%杜勇%李海%張東%楊銀學
왕위걸%장저매%두용%리해%장동%양은학
二甲肼%结直肠腺瘤%塞来昔布
二甲肼%結直腸腺瘤%塞來昔佈
이갑정%결직장선류%새래석포
1,2-dimethylhydrazine%Colorectal adenoma%Celecoxib
目的 观察选择性COX-2抑制剂塞来昔布对二甲肼(DMH)所诱导的SD大鼠结直肠腺瘤的抑制作用.方法 将80只雄性SD大鼠随机分为3组:空白组(20只):皮下注射与造模组DMH等量的生理盐水同时给予生理盐水4 ml灌胃,隔天1次;造模组(30只):皮下注射DMH(每周20 mg/kg)同时给予生理盐水4 ml灌胃,隔天1次;干预组(30只):DMH皮下注射量同模型组,同时给予塞来昔布(20mg/kg)灌胃,隔天1次,持续20周,各组于第10、14、18周分批处死实验大鼠(造模组、干预组各2只,空白组1只),进行苏木素-伊红(HE)染色,光镜下观察病理变化,20周后全部处死大鼠.结果 实验20周后,造模组大鼠体质量(297.7±6.4)g,低于空白组(352.7±5.3)g和干预组(325.2±5.1)g,差异均有统计学意义(P<0.01).预防组大鼠腺瘤数量和大小均低于造模组,差异有统计学意义(P<0.05).预防组大鼠腺瘤分布部位和组织类型与造模组比较,差异无统计学意义(P>0.05).结论 选择性COX-2抑制剂塞来昔布对二甲肼诱导的结直肠腺瘤有抑制作用.
目的 觀察選擇性COX-2抑製劑塞來昔佈對二甲肼(DMH)所誘導的SD大鼠結直腸腺瘤的抑製作用.方法 將80隻雄性SD大鼠隨機分為3組:空白組(20隻):皮下註射與造模組DMH等量的生理鹽水同時給予生理鹽水4 ml灌胃,隔天1次;造模組(30隻):皮下註射DMH(每週20 mg/kg)同時給予生理鹽水4 ml灌胃,隔天1次;榦預組(30隻):DMH皮下註射量同模型組,同時給予塞來昔佈(20mg/kg)灌胃,隔天1次,持續20週,各組于第10、14、18週分批處死實驗大鼠(造模組、榦預組各2隻,空白組1隻),進行囌木素-伊紅(HE)染色,光鏡下觀察病理變化,20週後全部處死大鼠.結果 實驗20週後,造模組大鼠體質量(297.7±6.4)g,低于空白組(352.7±5.3)g和榦預組(325.2±5.1)g,差異均有統計學意義(P<0.01).預防組大鼠腺瘤數量和大小均低于造模組,差異有統計學意義(P<0.05).預防組大鼠腺瘤分佈部位和組織類型與造模組比較,差異無統計學意義(P>0.05).結論 選擇性COX-2抑製劑塞來昔佈對二甲肼誘導的結直腸腺瘤有抑製作用.
목적 관찰선택성COX-2억제제새래석포대이갑정(DMH)소유도적SD대서결직장선류적억제작용.방법 장80지웅성SD대서수궤분위3조:공백조(20지):피하주사여조모조DMH등량적생리염수동시급여생리염수4 ml관위,격천1차;조모조(30지):피하주사DMH(매주20 mg/kg)동시급여생리염수4 ml관위,격천1차;간예조(30지):DMH피하주사량동모형조,동시급여새래석포(20mg/kg)관위,격천1차,지속20주,각조우제10、14、18주분비처사실험대서(조모조、간예조각2지,공백조1지),진행소목소-이홍(HE)염색,광경하관찰병리변화,20주후전부처사대서.결과 실험20주후,조모조대서체질량(297.7±6.4)g,저우공백조(352.7±5.3)g화간예조(325.2±5.1)g,차이균유통계학의의(P<0.01).예방조대서선류수량화대소균저우조모조,차이유통계학의의(P<0.05).예방조대서선류분포부위화조직류형여조모조비교,차이무통계학의의(P>0.05).결론 선택성COX-2억제제새래석포대이갑정유도적결직장선류유억제작용.
Objective To detect whether selective cyclooxygenase-2 inhibitor celecoxib could prevent SD rat colorectal adenomas induced by 1, 2-dimethylhydrazine ( DMH ). Methods Eighty male Sprague-Dawley rats were randomly divided into three groups: the control group (n = 20) , subcutaneous injection of equivalent saline with model group, gastric infusion of 4 ml saline once every other day; the model group (n =30), subcutaneous injection of DMH(20 mg/kg every week) , gastric infusion of 4 ml saline once every other day; the interferential group (n = 30), subcutaneous injection of equivalent DMH with model group, gastric infusion of celecoxib ( 20 mg/kg) once every other day. All animals received treatment for 20 weeks. The rats were killed in batches at the 10th, 14th and 18th week separately (one of the control group, two of the model group, two of the interferential group). The specimens were subjected to hematoxylin-eosin staining, and pathological changes were observed under the light microscopy. All remaining rats were killed at the 20th week. Results At the 20th week, the body weight of the rats in model group (297. 7 ± 6. 4) g was less than that in control group [ ( 352. 7 ± 5. 3 ) g ] and intefferential group [ (325.2 ±5. 1 ) g] (P <0. 01 ). The nu mber and size of colorectal adenomas in interferential group was reduced as compared with those in model group (P < 0. 05 ). On distribution site and histological type in the colorectal adenomas, there was no significant difference between control group and intefferential group (P >0. 05). Conclusion Celecoxib, a selective cyclooxygenase-2 inhibitor, may have preventive action against rat colorectal adenomas induced by DMH.